JP2021513974A5 - - Google Patents

Info

Publication number
JP2021513974A5
JP2021513974A5 JP2020543512A JP2020543512A JP2021513974A5 JP 2021513974 A5 JP2021513974 A5 JP 2021513974A5 JP 2020543512 A JP2020543512 A JP 2020543512A JP 2020543512 A JP2020543512 A JP 2020543512A JP 2021513974 A5 JP2021513974 A5 JP 2021513974A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
sequence number
Prior art date
Application number
JP2020543512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513974A (ja
JPWO2019158728A5 (https=
JP7808430B2 (ja
Filing date
Publication date
Priority claimed from GBGB1802487.7A external-priority patent/GB201802487D0/en
Application filed filed Critical
Publication of JP2021513974A publication Critical patent/JP2021513974A/ja
Publication of JPWO2019158728A5 publication Critical patent/JPWO2019158728A5/ja
Publication of JP2021513974A5 publication Critical patent/JP2021513974A5/ja
Priority to JP2024017576A priority Critical patent/JP2024063016A/ja
Application granted granted Critical
Publication of JP7808430B2 publication Critical patent/JP7808430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543512A 2018-02-15 2019-02-15 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト Active JP7808430B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024017576A JP2024063016A (ja) 2018-02-15 2024-02-08 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1802487.7A GB201802487D0 (en) 2018-02-15 2018-02-15 Cytokine combination therapy
GB1802487.7 2018-02-15
PCT/EP2019/053890 WO2019158728A1 (en) 2018-02-15 2019-02-15 Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024017576A Division JP2024063016A (ja) 2018-02-15 2024-02-08 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト

Publications (4)

Publication Number Publication Date
JP2021513974A JP2021513974A (ja) 2021-06-03
JPWO2019158728A5 JPWO2019158728A5 (https=) 2022-03-09
JP2021513974A5 true JP2021513974A5 (https=) 2022-03-09
JP7808430B2 JP7808430B2 (ja) 2026-01-29

Family

ID=61783635

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543512A Active JP7808430B2 (ja) 2018-02-15 2019-02-15 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト
JP2024017576A Pending JP2024063016A (ja) 2018-02-15 2024-02-08 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024017576A Pending JP2024063016A (ja) 2018-02-15 2024-02-08 Il-5/il-5r、及び、il-4/il-4r又はil-13/il-13rに対する組合せアンタゴニスト

Country Status (9)

Country Link
US (2) US12030949B2 (https=)
EP (1) EP3752529A1 (https=)
JP (2) JP7808430B2 (https=)
CN (1) CN112041342B (https=)
AU (1) AU2019221627B2 (https=)
CA (1) CA3088734A1 (https=)
GB (1) GB201802487D0 (https=)
IL (1) IL276344A (https=)
WO (1) WO2019158728A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
EP4165066A4 (en) * 2020-06-12 2024-08-14 Beijing Vdjbio Co., Ltd. FUSION POLYPEPTIDE
JP7743500B2 (ja) 2020-08-05 2025-09-24 シンセカイン インコーポレイテッド Il10受容体結合性分子および使用方法
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
WO2022032045A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL10Rα/IL2Rγ SYNTHETIC CYTOKINES
CN117903303A (zh) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 Il-5的结合分子及其应用
KR102697769B1 (ko) * 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
CN113307870B (zh) * 2020-10-30 2022-12-23 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
CN114605539B (zh) * 2020-12-09 2024-01-02 南京融捷康生物科技有限公司 人源化的抗IL-4Rα单域抗体及其应用
WO2022150791A2 (en) * 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to il2 receptor binding
CN114805572B (zh) * 2021-01-22 2022-12-13 上海济煜医药科技有限公司 抗原结合蛋白及其应用
CA3239182A1 (en) * 2022-05-23 2023-11-30 Zhipeng SU Stable antibody preparation
CN116606375B (zh) * 2023-07-03 2025-10-03 珠海瑞思普利医药科技有限公司 抗人白介素5纳米抗体及其应用
WO2026020024A1 (en) * 2024-07-19 2026-01-22 Bambusa Therapeutics, Inc. Multispecific binding agents and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
US20110008326A1 (en) 2008-04-02 2011-01-13 Oliver Hill Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2824111B1 (en) * 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A Antibodies and Methods for Using the Antibodies
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
PT2825559T (pt) 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
DK2847231T3 (da) 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3878964A1 (en) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
AU2014284235C1 (en) * 2013-06-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
US11261262B2 (en) 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105814082A (zh) 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
US20160272706A1 (en) * 2015-01-12 2016-09-22 Medimmune Limited Il-13 binding proteins and uses thereof
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
IL262241B2 (en) 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy

Similar Documents

Publication Publication Date Title
JP2021513974A5 (https=)
JP2024063016A5 (https=)
AU2022241522B2 (en) Bispecific antibody to a-syn/igf1r and use thereof
JP2022174314A (ja) 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP4541813A2 (en) Method of preparing ph-dependent antibodies
JPWO2019158728A5 (https=)
JP2012525829A5 (https=)
JP2010538608A5 (https=)
JP2021520825A5 (https=)
JP2021520825A (ja) ガレクチン−10抗体
JP2008527989A5 (https=)
JP6898251B2 (ja) 組換え抗体分子の単量体化方法
WO2019195313A1 (en) Anti-vegf antagonist and pedf agonist constructs and uses thereof
AU2021328375A1 (en) Anti-PAR-2 antibodies and methods of use thereof
ES3053942T3 (en) Anti-stem cell factor antibodies and methods of use thereof
CN106905431A (zh) 抗人补体d因子的单克隆抗体及其用途
CA3096791A1 (en) Cell engaging binding molecules
CA3200847A1 (en) Multi-specific antibodies and antibody combinations
CN114846026A (zh) 对人il-13和il-17具有结合特异性的多特异性抗体
TW202525846A (zh) 抗il—13多特異性抗體構築體及其用途
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
US20230374148A1 (en) Binding molecules that multimerise cd45
CA3200836A1 (en) Antibodies against interleukin-22
US20240117056A1 (en) Epidermal growth factor receptor variant iii antibodies
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use